BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10766297)

  • 1. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
    Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
    Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redox active disulfides: the thioredoxin system as a drug target.
    Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
    Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
    Kirkpatrick DL; Kuperus M; Dowdeswell M; Potier N; Donald LJ; Kunkel M; Berggren M; Angulo M; Powis G
    Biochem Pharmacol; 1998 Apr; 55(7):987-94. PubMed ID: 9605422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell line-directed screening assay for inhibitors of thioredoxin reductase signaling as potential anti-cancer drugs.
    Kunkel MW; Kirkpatrick DL; Johnson JI; Powis G
    Anticancer Drug Des; 1997 Dec; 12(8):659-70. PubMed ID: 9448705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural product based inhibitors of the thioredoxin-thioredoxin reductase system.
    Wipf P; Lynch SM; Birmingham A; Tamayo G; Jiménez A; Campos N; Powis G
    Org Biomol Chem; 2004 Jun; 2(11):1651-8. PubMed ID: 15162219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
    Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
    Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological activity of prodrug inhibitors of the thioredoxin-thioredoxin reductase system.
    Wipf P; Lynch SM; Powis G; Birmingham A; Englund EE
    Org Biomol Chem; 2005 Nov; 3(21):3880-2. PubMed ID: 16240002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
    Kłossowski S; Muchowicz A; Firczuk M; Swiech M; Redzej A; Golab J; Ostaszewski R
    J Med Chem; 2012 Jan; 55(1):55-67. PubMed ID: 22128876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semisynthetic maytansine analogues for the targeted treatment of cancer.
    Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
    J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
    Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
    Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of disulfides as anticancer agents with thioredoxin inhibition.
    Wei X; Zhong M; Wang S; Li L; Song ZL; Zhang J; Xu J; Fang J
    Bioorg Chem; 2021 May; 110():104814. PubMed ID: 33756234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 2. Effect of pyrrole-C2 and/or -C4 substitutions on biological activity.
    Mai A; Massa S; Cerbara I; Valente S; Ragno R; Bottoni P; Scatena R; Loidl P; Brosch G
    J Med Chem; 2004 Feb; 47(5):1098-109. PubMed ID: 14971890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth.
    McNaughton M; Engman L; Birmingham A; Powis G; Cotgreave IA
    J Med Chem; 2004 Jan; 47(1):233-9. PubMed ID: 14695837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
    Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
    J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel class of in vivo active anticancer agents: achiral seco-amino- and seco-hydroxycyclopropylbenz[e]indolone (seco-CBI) analogues of the duocarmycins and CC-1065.
    Sato A; McNulty L; Cox K; Kim S; Scott A; Daniell K; Summerville K; Price C; Hudson S; Kiakos K; Hartley JA; Asao T; Lee M
    J Med Chem; 2005 Jun; 48(11):3903-18. PubMed ID: 15916443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
    Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
    Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
    Tonissen KF; Di Trapani G
    Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disulfide and multisulfide antitumor agents and their modes of action.
    Lee SH
    Arch Pharm Res; 2009 Mar; 32(3):299-315. PubMed ID: 19387571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.